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Lung cancer in never-smokers is an important dis-
ease often characterized by mutations in epidermal
growth factor receptor (EGFR), yet risk reduction
measures and effective chemopreventive strategies
have not been established. We identify mammalian
target of rapamycin (mTOR) as potentially valuable
target for EGFR mutant lung cancer. mTOR is acti-
vated in human lung cancers with EGFR mutations,
and this increases with acquisition of T790M muta-
tion. In a mouse model of EGFR mutant lung cancer,
mTOR activation is an early event. As a single agent,
the mTOR inhibitor rapamycin prevents tumor devel-
opment, prolongs overall survival, and improves
outcomes after treatment with an irreversible EGFR
tyrosine kinase inhibitor (TKI). These studies support
clinical testing of mTOR inhibitors in order to prevent
the development and progression of EGFR mutant
lung cancers.INTRODUCTION
Lung cancer is the leading cause of cancer-related death in both
males and females in the United States, which is mostly related
to smoking. Nonetheless, 25% of all lung cancer cases
worldwide (15% of lung cancers in males and 53% in females)
are not attributable to smoking (Sun et al., 2007), which
makes lung cancer in never-smokers an important and common
problem. Molecular differences in lung cancers between
smokers and never-smokers have been identified. For example,
epidermal growth factor receptor (EGFR) mutations, echinoderm
microtubule-associated protein-like 4-anaplastic lymphoma ki-
nase fusions, ROS1 rearrangements (CD74-ROS1 fusion), and1824 Cell Reports 7, 1824–1832, June 26, 2014 ª2014 The Authorskinesin family member 5B-ret proto-oncogene fusions are
more likely to be identified in never-smokers (Johnson et al.,
2012).
Somatic mutations of EGFR in non-small-cell lung cancer
(NSCLC), such as point mutations in exon 21 (e.g., L858R) and
exon 19 deletions, are gain of function and enhance autophos-
phorylation of EGFR, resulting in EGFR-addicted lung cancers
that are sensitive to EGFR-specific tyrosine kinase inhibitors
(TKIs) (Sordella et al., 2004). Although profound responses are
observed with EGFR TKIs in patients with the activating somatic
EGFR mutations, these therapies are not curative. Continued
exposure to EGFR TKIs selects for resistant populations and/
or induces EGFR-TKI-resistant mechanisms in tumor cells (Pao
and Chmielecki, 2010). Emergence of tumors with a secondary
EGFR mutation in exon 20, T790M, is the most common mech-
anism of resistance to reversible EGFR TKIs, which is a vexing
clinical problem (Kobayashi et al., 2005; Pao et al., 2005). Strate-
gies to overcome EGFR TKI resistance by T790M include (1)
prevention of emergence of the resistant populations, (2) rechal-
lenge with TKIs after a drug holiday that may allow dilution or
disappearance of T790mutation in the absence of the TKI selec-
tion pressure, and (3) treatment of the resistant population with
second- or third-generation irreversible EGFR TKIs (Hirsch
et al., 2013). The concept of maintenance therapy for patients
with EGFR mutations treated with first-line EGFR TKI has not
been established.
The mammalian target of rapamycin (mTOR) is a serine/threo-
nine protein kinase that controls cell proliferation and survival
(Laplante and Sabatini, 2012). mTOR activity also contributes
to resistance to EGFR TKI in lung cancer cells (Fei et al., 2013).
Previously, we reported that rapamycin, an mTOR inhibitor, pre-
vented the development of tobacco-carcinogen-induced lung
tumors in a mouse model (Granville et al., 2007). These data
prompted us to hypothesize that mTOR inhibition will prevent
the emergence of EGFR-TKI-resistant populations with T790M
mutation. Here, we show that human NSCLC specimens with
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Figure 1. mTOR Is Activated in Human
NSCLC with EGFR Mutations
(A) Photomicrographs show representative staining
for phosphorylated S6 (Ser235/236) as a marker of
mTOR activation in two specimens with mEGFRL
(upper) or mEGFRL+T (lower). IHC was performed
as described in Supplemental Experimental Pro-
cedures. The scale bars represent 50 mm. See also
Figures S1A and S1B.
(B) Increased activation of mTOR in lung tumor
tissues with mEGFRL+T. The phosphorylated S6
staining index was established as described in
Supplemental Experimental Procedures. Columns:
mean of total 40 fields in lung tumor tissues
from four patients with mEGFRL (ten fields per
patient) or from four patients with mEGFRL+T. Bars:
SD. Two-tailed p value was obtained from unpaired
t test.EGFR mutations that subsequently acquire T790M mutation
have increased mTOR activation. In a series of preclinical
studies with a doxycycline-inducible, mutant EGFRL858R+T790M
(mEGFRL+T) lung cancer mouse model, we demonstrate that
rapamycin prevents the growth of T790M tumors, which was
associated with improved overall survival (OS), as well as
increased progression-free survival (PFS) andOS after treatment
with an irreversible EGFR TKI.
RESULTS
mTOR Is Activated in Human NSCLC with EGFR
Mutations
We analyzed a series of human NSCLC specimens with mutant
EGFRL858R (mEGFRL) or mEGFRL+T for phosphorylation of the
ribosomal protein, S6, using immunohistochemistry. All 11
NSCLC specimens showed mTOR activation (Figures 1A,
S1A, and S1B). mEGFRL+T specimens had increased phosphor-
ylation of S6 compared to those with mEGFRL (p = 0.0006;
Figure 1B), indicating greater mTOR activation in lung cancers
expressing mEGFRL+T and suggesting that mTOR inhibitors
might prevent emergence of mutant EGFR lung cancers with
T790M mutation.
Role of mTOR in Established Mutant EGFR-Driven Lung
Tumors and during Lung Tumor Regression Caused by
Doxycycline Withdrawal
To determine if mTOR could be a therapeutic target in estab-
lished mutant EGFR-driven lung tumors, mEGFRL+T mice were
treated with vehicle or rapamycin. Disease progression was
observed in both groups (Figure 2A), despite the fact that
mTOR was inhibited by rapamycin (Figure 2B). This demon-
strates that mTOR inhibition alone is insufficient to cause regres-
sion of established mutant EGFR-driven lung tumors.
The continued expression of EGFRL+T in this mouse model is
dependent on the administration of doxycycline (Dox). To assess
the role of mTOR in mutant EGFR-induced tumor maintenance,
we measured activation of EGFR and the downstream signalingCpathways upon Dox withdrawal. Lung tumor regression was
observed after 5 days of Dox withdrawal (Figures 2C and S1C).
Dox withdrawal decreased expression and activation of EGFR,
as well as extracellular signal-regulated kinases (ERK1/2), which
was associated with increased cleaved PARP, a marker of
apoptosis. In contrast to ERK, activation of Akt/mTOR was not
decreased by Dox withdrawal (Figure 2D), indicating that the
Akt/mTORpathway is independent of EGFR signaling. To assess
the mechanism by which activation of Akt and mTOR are main-
tained during regression, activation of the insulin-like growth fac-
tor 1 receptor (IGF-1R) was assessed. Increased activation of
IGF-1R was observed 2 days after Dox withdrawal (p < 0.01;
Figure 2E), implicating activated IGF-1R in the maintenance of
Akt/mTOR activation. To confirm that activation of IGF-1R was
a local event related to lung tumor regression, the status of
IGF-1R in liver samples from the same mice in Figure 2E was
assessed. IGF-1R was not activated in liver tissues (Figure 2F).
Taken together, these data suggest that activation of the Akt/
mTOR pathway is maintained by IGF-1R activation to compen-
sate for EGFR/ERK1/2 deactivation during regression of mutant
EGFR-driven lung tumors in a futile attempt to maintain survival
of tumor cells.
Rapamycin Prevents Tumorigenesis in mEGFRL+T Mice
Previously, we reported that rapamycin prevented the develop-
ment of tobacco-carcinogen-induced lung tumors in a mouse
model (Granville et al., 2007). If mTOR inhibition was to prevent
tumorigenesis inmEGFRL+Tmice, we hypothesized that it should
be an early event. Therefore, we assessed mTOR activation in
lung lysates prior to tumor development. Dox induced expres-
sion of mutant EGFR and activated the EGFR/Akt/mTOR
pathway (Figure 3A), but not EGFR/ERK1/2 signaling, suggest-
ing that Akt/mTOR activation is an early event in EGFR-addicted
lung tumorigenesis. These results strengthened our hypothesis
that mTOR inhibition will prevent mutant EGFR-driven lung
cancers.
To test this, a study was performed with rapamycin using a
dosing regimen that yields trough drug levels that are wellell Reports 7, 1824–1832, June 26, 2014 ª2014 The Authors 1825
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tolerated in humans (Granville et al., 2007). After confirming that
rapamycin did not decrease transgene expression (Supple-
mental Results; Figures S1D and S1E) in the mEGFRL+T mouse
model, mEGFRL+T mice were randomized to vehicle or rapamy-
cin (Figure 3B; Table S1A). At 8 weeks, rapamycin decreased
lung tumor incidence by 47.6% (p < 0.0001; Figure 3C) and total
tumor volume (TV) by 98% (p < 0.0001; Figure 3D). Treatment
with rapamycin was continued until signs of distress appeared,
which mandated euthanasia (Figure S2A). Median OS was not
reached in the rapamycin group, but compared to the vehicle
group, the median OS was prolonged by more than 3-fold (p <
0.0001; Figure 3E), which was inversely correlated to TV (Fig-
ure S2B; Table S1B), suggesting that prolongation of survival
was due to inhibition of tumor growth. When the last mouse in
the vehicle group died, the remaining mice in rapamycin group
were evenly distributed based on tumor size and randomized
to continued rapamycin or vehicle (Figures S2C–S2E; Table
S1C). Mice switched to vehicle had shorter OS than continued
rapamycin (p = 0.031; Figure 3F), indicating that continuous
exposure to rapamycin is required for clinical benefit and
prolongation of survival. Collectively, these findings show that
rapamycin is highly effective to prevent lung tumorigenesis in
mEGFRL+T mice.
Markers of Rapamycin Resistance
Because the mice on rapamycin treatment eventually die of lung
cancers, resistance mechanisms to rapamycin were examined.
Rapamycin-resistant tumors maintained mTOR inhibition, as
assessed by two phosphorylation sites of S6, as well as in-
creased expression of hypophosphorylated forms of 4E-BP1
(Figure 3G). Feedback activation of Akt was not observed.
Because mTOR signaling induces differentiation of human em-
bryonic stem cells (Easley et al., 2010), we assessed markers
of undifferentiated tumor cells. Rapamycin-resistant tumors
had increased expression of lung stem cell markers such as
Oct-4 and SOX2, as well as increased activation of a
Notch pathway comprised of Stat3/p63/Jagged1/Notch/HES1/
c-Myc/Numb (Ma et al., 2010). Increased expression of vimentin,
a mesenchymal marker, was also observed (Figure 3H). Other
mechanisms reported to be related to EGFR TKI resistance
such as increased expression of SKP2, Bim, and her3 were not
observed (data not shown). These results suggest that rapamy-
cin resistance is associated with the selection or induction of
pluripotent tumor cells.Figure 2. Role of mTOR in Established Mutant EGFR-Driven Lung Tu
Withdrawal
(A) Treatment with rapamycin alone is ineffective in the established mutant EGFR
scanned by micro-CT, and were treated with vehicle or rapamycin for 5 days and
chemoprevention study. H, heart; L, left side. Red arrows indicate dense areas o
(B) mTOR inhibition in lung tumors extracted after 3 hr after last rapamycin admi
(C) Dox withdrawal induces regression of mEGFRL+T-driven lung tumors. CT ima
three mice administrated on Dox for 7 weeks. Red arrows indicate dense areas
(D) The activation of Akt/mTOR pathway is maintained during mEGFRL+T-driven
C/L858R+T790M mice were extracted on the indicated days after Dox withdraw
(E and F) IGF-1R is activated by Dox withdrawal for 2 days (2d) in lung tissues
Densitometry analysis was performed using ImageJ software, and levels of each
Columns: mean from all three mice examined in on Dox 7 weeks or off Dox 2d gro
tailed unpaired t test. **p < 0.01.
CRapamycin Prolongs PFS and OS after Treatment with
an Irreversible EGFR TKI
The issue of discontinuous therapy with an EGFR TKI to delay
emergence of T790M mutation is controversial. For example,
patients with acquired resistance to reversible EGFR TKIs
showed reresponse to the TKI therapy after a drug holiday
(Hirsch et al., 2013), whereas Chaft et al. (2011) reported discon-
tinuation of erlotinib or gefitinib (first-generation reversible EGFR
TKIs) led to accelerated disease progression referred to ‘‘dis-
ease flare’’. Because rapamycin prevented development of
mutant EGFR lung tumors with T790M mutation, we hypothe-
sized that rapamycin might be beneficial as an interventional
therapy during a TKI-free period following EGFR TKI treatment.
Such an approach might prevent disease flare and prolong PFS.
To test this hypothesis, we performed a switch maintenance
study with rapamycin following treatment of mEGFRL+T mice
with a third-generation irreversible EGFR TKI, WZ4002 (Zhou
et al., 2009; Figure 4A). WZ4002 rapidly and efficiently inhibited
EGFR activation, as well as activation of Akt, ERK, and mTOR
(Figure 4B). The design of the maintenance study is as follows.
Twenty-four C/L858R+T790M mice were treated with Dox for
5 weeks, at which time lung tumors were documented by
micro-computed tomography (CT). Mice were then treated
withWZ4002 for 5 days and divided into treatment groups based
on equal distribution of tumor volumes. After 5 days, WZ4002
was stopped andmice were randomized to vehicle or rapamycin
(Figures S2F–S2H; Table S2). WZ4002 effectively treated estab-
lished tumors, with a 100% response rate and average reduction
in tumor volume of approximately 80% (Figure S2H). Mice ran-
domized to vehicle showed rapid progression, but mice treated
with rapamycin had delayed disease progression (Figure 4C).
Rapamycin prevented disease flare (p = 0.0006; Table S2), de-
layed the percent increase of TV over time (p = 0.030; Figure S2I),
and prolonged PFS (p = 0.014; Figure 4D). Treatment with rapa-
mycin also prolonged OS (p = 0.0007; Figure 4E) and was asso-
ciated with sustained mTOR inhibition during this maintenance
study (Figure S2J). To assess whether rapamycin exerted direct
effects on epithelial cells or worked independently, in vitro exper-
iments were performed in H1975 and H820 cells that have
T790M EGFR mutation. In each cell line, an LD80 was estab-
lished for WZ4002. After treatment and subsequent washout
with WZ4002, cells were treated with vehicle or rapamycin.
Rapamycin markedly diminished cell proliferation (Supplemental
Results and Figures S3 andS4A), which correlatedwith inhibitionmors and during Lung Tumor Regression Caused by Doxycycline
-driven lung tumors. Six C/L858R+T790M mice were given Dox for 7 weeks,
then rescanned. The dosing and schedule of rapamycin were the same as the
f lung tumors.
nistration in (A). IB was performed using the indicated antibodies.
ges show tumor regression before and after Dox withdrawal for 5 days (5d) in
of lung tumors. See also Figure S1C.
lung tumor regression. After Dox administration for 7 weeks, lung tumors from
al. IB was performed using the indicated antibodies. See also Figure S1C.
(E), but not liver tissues (F). IB was performed using the indicated antibodies.
marker were normalized to total expression and/or GAPDH for each sample.
up. Bars, SD. Statistical analysis of the densitometry was performed with two-
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of EGFR as well asmTOR signaling (Figure S4B), suggesting that
rapamycin exerts direct effects on EGFR mutant lung cancer
cells. Taken together, our results show that rapamycin prevents
disease flare during an EGFR-TKI-free period after TKI treatment
and prolongs time to disease progression as well as OS.
DISCUSSION
mTOR is progressively activated in human lung cancers with
T790M mutation and is an early event in a murine model of
lung tumorigenesis. We demonstrate that rapamycin decreases
the incidence of mutant EGFR-driven lung tumors and prolongs
survival and prevents disease progression of lung cancers after
EGFR TKI treatment. This study describes the involvement of
mTOR activation in EGFR-addicted lung tumorigenesis and
shows that rapamycin prolongs PFS and OS. Although rapamy-
cin can extend the lifespan of mice (Harrison et al., 2009), we
contend that rapamycin prolongs OS in our studies by inhibiting
lung cancer mortality rather than by extension of the overall life-
span, becausemTOR inhibitionwas still observed in tumors from
mice that progressed on rapamycin treatment (Figures 3G and
S2J), and OS was inversely correlated to TV (Figure S2B).
Although T790Mmutation accounts for approximately 50% of
acquired EGFR TKI resistance, when tumor cells acquire the
resistant mutation remains unclear. Recent reports have identi-
fied T790M mutation in 25.2% and 31.5% of EGFR-TKI-naive
and pre-TKI samples, respectively, implying that the incidence
of T790M may be higher than expected (Su et al., 2012) and
that the presence of somatic T790M mutation before treatment
might cause primary resistance to reversible EGFR TKIs (Ohashi
et al., 2013). This suggests that an mTOR inhibitor might prevent
outgrowth of tumors with T790Mmutation. Moreover, rapamycin
prevented disease flare during a TKI-free period following EGFR
TKI treatment and prolonged PFS in our preclinical switch
maintenance study (Figure 4D and Table S2), suggesting that in-
hibition of mTOR might prevent disease flare caused by ‘‘drug
holidays’’ or intermittent therapy in advanced NSCLC patients
with EGFR mutations.
Although rapamycin decreased tumor incidence and TV and
markedly prolonged OS in this study, mice on rapamycin even-
tually die of lung cancer. Unexpectedly, we did not observe
mechanisms of resistance such as feedback activation of AktFigure 3. Rapamycin Prevents Tumorigenesis in mEGFRL+T Mice
(A) mTOR activation following the induction of mutant EGFR precedes lung tum
3 weeks, and then the normal lungs were extracted. IB was performed using the
(B) Schema of chemoprevention study. See also Table S1A.
(C) Rapamycin decreases lung tumor incidence. After 8 weeks of vehicle or rapa
tumors were detected in 100% of mice (21/21) in vehicle-treated and in 52.4% of r
also Table S1B.
(D) Rapamycin decreases TV. TV was calculated after 8 weeks of vehicle or rapam
two-tailed, p < 0.0001. For the dot plots, each point represents a mouse and the
(E) Rapamycin prolongs OS in the chemoprevention study. Median survival in ve
represents 12 remaining mice in rapamycin group at 182 days for a rapamycin w
(F) Continuation of rapamycin is required for OS prolongation in the rapamycin w
Figure 3E. Median survival in vehicle and continued rapamycin group was 62 da
(G and H) Tumors from mice that progressed on rapamycin maintain mTOR in
signaling, and vimentin. Three mice in vehicle group were from the chemopreventi
group were from the rapamycin withdrawal study in (F). See also Table S1C. Lung
C(Laplante and Sabatini, 2012; Figures 3G and S2J). Inhibition of
mTOR was sustained, even at the point of death, demonstrating
that rapamycin maintained adequate intracellular levels to inhibit
downstream signaling from mTOR. Because prolonged stimula-
tion of mTOR can lead to stem cell depletion through the activa-
tion of senescence programs, the use of mTOR inhibitors might
protect adult stem cells from initiating premature cell senes-
cence programs (Iglesias-Bartolome and Gutkind, 2012). This
is consistent with our observation that long-term treatment
with rapamycin increased expression of stem cell markers
such as Oct-4 and SOX2, increased activation of a Notch
pathway, and increased expression of mesenchymal markers
such as vimentin (Figure 3H). This implicates pluripotent tumor
cells in rapamycin resistance.
In summary, our study highlights the importance of mTOR
activation as an early event in EGFR-addicted lung tumorigen-
esis and the efficacy of rapamycin as an agent to prevent the
development or progression of EGFR mutant lung cancers.
These results can be used to develop strategies to incorporate
mTOR inhibitors into clinical trials with EGFR TKI to prevent the
emergence of lung cancers with T790M mutation.
EXPERIMENTAL PROCEDURES
Mouse Cohort and Genotyping
All experiments were conducted under a protocol approved by the National
Cancer Institute (NCI) Animal Care and Use Committee. National Institutes
of Health (NIH) is an Association for Assessment and Accreditation of Labora-
tory Animal Care-certified facility. The generation of bitransgenic progeny
(harboring the Clara cell secretory protein (CCSP)-reverse tetracycline respon-
sive transactivator (rtTA) and tet-regulated EGFRL858R+T790M transgenes;
‘‘C/L858R+T790M’’) has been previously described (Regales et al., 2007).
CCSP-rtTA and EGFR genotype was assessed by PCR from tail clips (Floyd
et al., 2005; Politi et al., 2006). The expression of mEGFRL+T was assessed
by immunoblotting (IB) and immunohistochemical analysis (IHC) with an anti-
body to EGFR (L858Rmutant specific; 43B2). All mice were housed in specific
pathogen-free housing with NIH-31 regular diet and autoclaved water ad libi-
tum. For all experiments, mice were fed doxycycline-impregnated food pellets
(NIH-31 regular diet with 650 ppm doxycycline; Harlan-Teklad) to induce
expression of mutant EGFR.
Chemoprevention Study
Forty-two 14-week-old C/L858R+T790M mice were randomized to vehicle or
rapamycin group based on both their gender and age. Rapamycin (LC Labo-
ratories) was formulated in vehicle (5% Tween 80 and 5% polyethylene glycolor development. Six C/L858R+T790M mice received normal diet or Dox for
indicated antibodies. mTOR activation was measured by phosphorylated S6.
mycin treatment, lung-tumor-bearing mice were identified by micro-CT. Lung
apamycin-treated mice (11/21). Fisher’s exact test, two-tailed, p < 0.0001. See
ycin treatment as described in Experimental Procedures. Mann-Whitney test,
lines represent the median values. See also Table S1B.
hicle group was 65 days but had not been reached in rapamycin group. Arrow
ithdrawal study. HR, hazard ratio. See also Table S1B.
ithdrawal study. Arrow represents 12 remaining mice in rapamycin group from
ys and 140 days, respectively. See also Figure S2C and Table S1C.
hibition but show the increased expression of lung stem cell markers, Notch
on study in (B). See also Table S1B. On the other hand, three mice in rapamycin
tumors were extracted, and IB was performed using the indicated antibodies.
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Figure 4. Rapamycin Prolongs PFS and OS after Treatment with an Irreversible EGFR TKI
(A) Schema of switch maintenance therapy. See also Table S2.
(B) WZ4002 inhibits EGFR and the downstream Akt/mTOR pathway in mEGFRL+T-driven lung tumors. As a biomarker study, six lung-tumor-bearing
C/L858R+T790M mice on Dox for 7 weeks were given two doses of vehicle or WZ4002 (25 mg/kg once a day) by gavage. Lung tumors were extracted 3 hr after
last administration. IB was performed using the indicated antibodies. (Note: the two doses administration of WZ4002 did not induce tumor regression; data not
shown).
(C) Two representative mice from the switch maintenance study. Mouse no. 8699 in vehicle group showed PD by day 14; on the other hand, rapamycin prevented
disease progression to day 55 in mouse no. 6009. PR, partial response. Red arrows indicate dense areas of lung tumors. See also Table S2.
(D) Rapamycin prolongs PFS. PD of mice in vehicle or rapamycin groups was assessed by criteria to classify tumor responses as described in Supplemental
Experimental Procedures. Median PFS in vehicle and rapamycin group was 13.0 days and 17.5 days, respectively. See also Table S2.
(E) Rapamycin prolongs OS. Median OS in vehicle and rapamycin group was 37 days and 68 days, respectively. See also Table S2.in 0.9% NaCl to yield a final concentration of 4% DMSO from Sigma) and in-
jected intraperitoneally at 1.5 mg/kg every other day following a 4.5 mg/kg
loading dose as described previously (Granville et al., 2007). Tumor-bearing
mice were identified by micro-CT after 8 weeks of rapamycin treatment (pri-
mary end point: lung tumor incidence). The vehicle or rapamycin treatment
was continued to assess OS as the secondary end point. For all studies,
mice that showed respiratory distress and reduced motility were euthanized.
Day 1 for OS was the date when the 42 C/L858R+T790M mice were random-1830 Cell Reports 7, 1824–1832, June 26, 2014 ª2014 The Authorsized. Day 182 was the end date of this chemoprevention study when the last
mouse in vehicle group died.
Rapamycin Withdrawal Study
After all mice in the vehicle group in the chemoprevention study had died, 12
remaining C/L858R+T790M mice in rapamycin group were evenly distributed
based on tumor size and randomized to vehicle or continued rapamycin group.
The dosing and schedule of rapamycinwere the same as the chemoprevention
study. The primary end point was OS. Day 1 for OS was the date when the 12
mice were randomized. Day 190 was the end date of rapamycin withdrawal
study when the last mouse in continued rapamycin group died.
Switch Maintenance Study
Micro-CT scans were performed on 24 11-week-old C/L858R+T790Mmice on
Dox for 5 weeks. All mice had lung tumors and were treated with WZ4002 by
gavage at 50 mg/kg twice a day for 5 days and then were rescanned by micro-
CT to assess tumor regression. WZ4002 was formulated in vehicle (10%
1-methyl-2-pyrrolidinone and 90% polyethylene glycol-300 from Sigma). All
WZ4002-responding mice were randomized to vehicle or rapamycin group
based on the status of lung tumors. The dosing and schedule of rapamycin
were the same as the chemoprevention study. To assess PFS as the primary
end point, mice were monitored by micro-CT once a week until disease pro-
gression. When mice showed progression, monitoring was stopped but the
switch maintenance therapy with rapamycin was continued to assess OS as
a secondary end point. Once a mouse showed respiratory distress and
reduced motility, it was euthanized. Disease flare in this preclinical study
was defined as progressive disease (PD) that occurred earlier than median
PFS in vehicle group (13.0 days). Day 1 for both PFS and OS was the date
when the 24 WZ4002-responding mice were randomized. Day 160 in OS
was the end date of the switch maintenance study when the last mouse in
rapamycin group died.
Patients
Lung cancer specimens of patients with NSCLCwere obtained from the Dana-
Farber Cancer Institute. Tumor tissues with mEGFRL were from four patients in
pre-erlotinib treatment, whereas those with mEGFRL+T were from other seven
patients treated with erlotinib, who showed erlotinib resistance. Information on
gender, age, and histology was available for most samples. The approval of
the institutional review board of Dana-Farber Cancer Institute was obtained
for all studies.
Statistics
All analyses were performed using the GraphPad Prism software version 5.0c
(GraphPad Software). OS and PFS curves were created by the Kaplan-Meier
method. Comparisons of two survival curves were performed with the log
rank test. Correlation analyses were performed with Pearson (r: Pearson r).
p values of less than 0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental Results, four figures, and two tables and can be found with
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